But the extensively curated dataset covering its anti-PD-L1 ADC raises more questions.
ApexOnco Front Page
Recent articles
As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?
Gilead’s TROP2 ADC sets the bar for Astra/Daiichi’s Datroway in first-line TNBC.
Any hopes of differentiation could come down to side effects.
BNT142 looks lacklustre, but the company still sees promise in mRNA-encoded bispecifics.
DZD8586 shows some evidence that it can rescue BTK failures, but its precise role remains unclear.
Early data on SSGJ-707 in PD-L1-positive lung cancer spur comparisons against ivonescimab.
The Breakwater study hits on overall survival with "unprecedented" data.
